Appropriately critical commentary on cochrane reviews as the apply to matched targeted therapy by @viveksubbiah.bsky.social Journal of Clinical Oncology ascopubs.org/doi/full/10....

PFS benefit noted with adagrasib

10 Must-Read Posts in Immuno-Oncology This Week @viveksubbiah.bsky.social @jiajennyliu.bsky.social @gerryhanna.bsky.social @drjnaidoo.bsky.social oncodaily.com/oncolibrary/... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #IO #ImmuneOncology

Nature Medicine Study on Molecular Profiling in Meningioma - @viveksubbiah.bsky.social oncodaily.com/science/vive... #OncoDaily #Oncology #Cancer #Health #Medicine

Rare Cancers Deserve Breakthroughs Too - Vivek Subbiah @viveksubbiah.bsky.social @conquercancer.bsky.social oncodaily.com/blog/rare-ca... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Top Articles Suggested by Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/voices/vivek... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

🔊 Listen to Jiyoung Ahn, PhD, of New York University, discuss with @viveksubbiah.bsky.social, MD, about whether the oral bacterial and fungal microbiome is associated with the development of pancreatic #cancer. Listen now: ja.ma/41Vzuh9

Congratulations to Petros Grivas on Being Named Medical Director of Fred Hutch Cancer Center - Vivek Subbiah @viveksubbiah.bsky.social @fredhutch.org oncodaily.com/career/vivek... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Top 5 Articles of the Week Suggested by Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/voices/vivek... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial - The Lancet www.thelancet.com/journals/lan...

Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study - The Lancet Oncology www.thelancet.com/journals/lan...

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol - The Lancet Oncology www.thelancet.com/journals/lan...

What is Missing to Fully Harness Precision Medicine and Transform Cancer Care - Vivek Subbiah @viveksubbiah.bsky.social @natmed.nature.com oncodaily.com/blog/vivek-s... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #PrecisionMedicine

It’s Time We Evolve WHO Cancer Classification - Vivek Subbiah @viveksubbiah.bsky.social @who.int oncodaily.com/science/vive... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CancerClassification #WHO

How Clinical Trials Offer Hope for Those Facing Limited Options - Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/blog/clinica... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ClinicalTrial #Sarcoma #SarcomaAwarenessMonth

⭐️Tissue-agnostic cancer therapies: promise, reality, and the path forward @natcomms.nature.com @ascocancer.bsky.social #ASCO25 www.nature.com/articles/s41...

🚨 Hot off the press! 🚨 The @myesmo.bsky.social ESMO Precision Oncology Working Group, has unveiled key "Recommendations for structuring Molecular Tumour Boards (MTBs) in clinical practice", now published in ESMO's flagship journal Annals of Oncology 🧬🏥 www.annalsofoncology.org/article/S092...

Cancer Isn’t Just a Human Disease – It’s a Biological Reality Across Species, From Dogs to Tigers to the Extinct Dinosaurs - Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/blog/vivek-s... #OncoDaily #Oncology #Cancer #Medicine #Health

25 Posts Not to Miss from EHA 2025 @nicogagelmann.bsky.social @talhabadarmd.bsky.social @majorajay.bsky.social @vincentrk.bsky.social @viveksubbiah.bsky.social @nejm.org oncodaily.com/societies/eh... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EHA2025 #EHA25

Why Every Rare Cancer Patient Deserves Molecular Profiling? - Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/insight/vive... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #RareCancers #MolecularProfiling

Super interesting. "Tissue-agnostic #cancer therapies promise 2 revolutionize oncology by targeting molecular drivers. [A] study of nearly 300K tumors found 21.5% w/tissue-agnostic indications. Despite 9 #FDA approvals, real-world implementation challenges ..." 1/2 #CanSky #OncSky #ASCO25

⭐️Tissue-agnostic cancer therapies: promise, reality, and the path forward @natcomms.nature.com @ascocancer.bsky.social #ASCO25 www.nature.com/articles/s41...

ASCO and Google create ‘walled garden’ AI tool for doctors to query group’s guidelines www.statnews.com/2025/05/21/a... via @statnews.com

Honored to Work Alongside an Incredible Team of Investigators Dedicated to Ending Cancer - Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/blog/team-of... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ClinicalTrialsDay #ASCO25

Inspiring Journey of the 2024 Yvonne Awardees - A Year of Impact and Leadership @drasyaagulnik.bsky.social @viveksubbiah.bsky.social oncodaily.com/blog/yvonne-... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Yvonne #Leadership

⭐️To all the incredible moms who fill our lives with love, strength, and wisdom-today is for you. 🙏🏽Thank you for being the heart of every home & the foundation of so many dreams. Happy Mother’s Day! 💐❤️ #MothersDay

Exhilarating discussions on new podcast: Immunoverse - Vivek Subbiah @viveksubbiah.bsky.social @patrickhwumd.bsky.social @moffittnews.bsky.social oncodaily.com/blog/immunov... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Immunoverse #Podcast

Excited to be part of this #AACR25 (@theaacr.bsky.social @rickbuck.bsky.social) Social Media Ambassadorship!! Look out for updates on the #Tumor-microenvironment ( #TME )-relevant events and highlights. I’ll be posting from Sunday afternoon to midday Wednesday 😎

🚨The #AACR25 buzz is building! I’m thrilled to be a Social Media Ambassador for this year’s #AACR Annual Meeting. 👉🏼Please join me & all the ambassadors as we spotlight the exciting science. Research matters—and so does sharing it. Join the convo with @theaacr.bsky.social @rickbuck.bsky.social

Excited and honored to be a Social Media Ambassador for @theaacr.bsky.social #AACR25 Follow along with me here and on LinkedIn to experience the Annual Meeting with me starting this Friday in Chicago. Kicking off with #AACRAMC Grant Writing Workshop Friday afternoon! #AACRECR go.bsky.app/Jj6Efme

Abstracts are out for #ASCO25! 5000+ studies. 5 Plenary game-changers. @ascocancer.bsky.social @oncoalert.bsky.social @drchoueiri.bsky.social @ptarantinomd.bsky.social @viveksubbiah.bsky.social @oncbrothers.bsky.social

We're so excited about #AACR25 that we just created a starter pack for all their Social Media Ambassadors on #MedSky - almost all are here! Follow these leaders here for all the AACR lowdown: go.bsky.app/Jj6Efme

Hot off the press in @ascocancer.bsky.social journal JCO Oncology Advances: Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches ascopubs.org/doi/10.1200/... from our University of Minnesota group led by Dr. Ajay Prakash - #Immunoonc #immunotherapy

🚨🚨🚨Pleased to share our article in @ascocancer.bsky.social Ed book 👉🏼Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras 🦓🦓🦓 ascopubs.org/doi/10.1200/...

🚨 Hot off the press! 🚨 The @myesmo.bsky.social ESMO Precision Oncology Working Group, has unveiled key "Recommendations for structuring Molecular Tumour Boards (MTBs) in clinical practice", now published in ESMO's flagship journal Annals of Oncology 🧬🏥 www.annalsofoncology.org/article/S092...

📢 Agenda Spotlight: Plenary Session Are tumor-agnostic therapies the future of cancer treatment? Dr. @viveksubbiah.bsky.social will explore this evolving shift at **Great Debates in Solid Tumors**. Join the conversation: www.hmpglobalevents.com/gdst #GDST25 #MedicalEducation #GreatDebates #Cancer

Proud to collaborate with @scrinetwork.bsky.social at Great Debates in Solid Tumors! Join Co-Chairs @erikahamilton9.bsky.social & @drkatymoore.bsky.social, plus Andrew McKenzie PhD, & @viveksubbiah.bsky.social, leading key discussions on solid tumors. 🔗 gdsolidtumors.com #Oncology #CancerResearch

🚨 Precision Dosing IS Precision Oncology 🧬💡 An editorial in Annals of Oncology by Dr. @viveksubbiah.bsky.social reframes precision oncology, arguing that “precision dosing is precision oncology.” 👇 #Onco404 #Oncology #Cancer #PrecisionOncology #CancerResearch #PersonalizedMedicine

📢 It has been a learning experience over the past 3 days at #ESMOTAT25 to listen to experts in the field of #phaseI #drugdevelopment 🗣️ The talks were truly insightful ✅ New and improved drugs 🎯 📊 Innovative trial designs @myesmo.bsky.social @viveksubbiah.bsky.social @oncoalert.bsky.social

Check out Dr. @viveksubbiah.bsky.social's insights on managing #FGFR inhibitor side effects. Proactive monitoring is key to better outcomes in #urothelialcarcinoma and #cholangiocarcinoma: bit.ly/4129EXD Dr. Subbiah is also faculty at #GDST → www.hmpglobalevents.com/gdst #MedicalEducation #Cancer

The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials - Vivek Subbiah @viveksubbiah.bsky.social @weldeiry.bsky.social oncodaily.com/blog/vivek-s... #JCO #Oncology #OncoDaily #Cancer #Medicine #Health

A testament to the power of global collaboration in advancing healthcare - Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/insight/vive... #Cancer #OncoDaily #Oncology #WorldCancerDay #Medicine #Health

Revolutionizing Cancer Therapy – Breaking Barriers in Oncology with Tumor-Agnostic Drug Development - Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/blog/vivek-s... #Cancer #OncoDaily #Oncology #Medicine #Health

⭐️Evidence for a reduction in number of cycles of immune checkpoint inhibitors - The Lancet Oncology www.thelancet.com/journals/lan...

⭐️FDA approves new non-opioid pain drug. The FDA has approved Vertex’s suzetrigine (Journavx), an oral inhibitor of voltage-gated sodium channel 1.8 (NaV1.8), for the treatment of moderate to severe acute pain. www.nature.com/articles/d41...

5 articles suggested by Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/insight/vive... #Cancer #CancerResearch #Oncology #OncoDaily #Medicine #Health

🚨Hot of the press 👉🏼 Pleased to share our latest commentary in @natureportfolio.bsky.social NRCO 👉🏼 "Transforming Pediatric AML Trials: From Failing One-Size-Fits-All Methods to Precision Oncology” Thrilled to collaborate w the amazing Dr. Branko Cuglievan on this! www.nature.com/articles/s41...

🚨🥁🥁🥁Published online Live now on #FOXNEWS 👉🏼So excited to share the latest & greatest in cancer research in 2024 and what’s ahead in 2025 @foxnewscorporation.bsky.social Link : www.foxnews.com/health/year-...

Top Phase 1 clinical trial publications of 2024 - Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/insight/217361 #OncoDaily #Oncology #Medicine #Health #Cancer #CancerResearch

🔗 : ascopubs.org/doi/10.1200/... 🙏 for the wonderful collaboration and mentorship from many experts around the globe! @anthonymjoshua.bsky.social @oncocook.bsky.social @weldeiry.bsky.social @sarahblagden.bsky.social @viveksubbiah.bsky.social @oncoalert.bsky.social @oncodaily.bsky.social